Global RNAi Technologies, Markets and Companies Report 2016-2025 with Profiles of 162 Companies & 235 Collaborations - Research and Markets
DUBLIN, Dec 1, 2016 /PRNewswire/ --
Research and Markets has announced the addition of Jain PharmaBiotech's new report "RNAi - Technologies, Markets and Companies" to their offering.
The markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials. The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development. Various markets relevant to RNAi are analyzed from 2015 to 2025. Markets are also analyzed according to technologies and use of siRNAs, miRNAs, etc.
Various RNAi technologies are described, along with design and methods of manufacture of siRNA reagents. These include chemical synthesis by in vitro transcription and use of plasmid or viral vectors. Other approaches to RNAi include DNA-directed RNAi (ddRNAi) that is used to produce dsRNA inside the cell, which is cleaved into siRNA by the action of Dicer, a specific type of RNAse III. MicroRNAs are derived by processing of short hairpins that can inhibit the mRNAs. Expressed interfering RNA (eiRNA) is used to express dsRNA intracellularly from DNA plasmids.
Delivery of therapeutics to the target tissues is an important consideration. siRNAs can be delivered to cells in culture by electroporation or by transfection using plasmid or viral vectors. In vivo delivery of siRNAs can be carried out by injection into tissues or blood vessels or use of synthetic and viral vectors.
Regulatory, safety and patent issues are also discussed. Side effects can result from unintended interaction between an siRNA compound and an unrelated host gene. If RNAi compounds are designed poorly, there is an increased chance for non-specific interaction with host genes that may cause adverse effects in the host. However, there are no major safety concerns and regulations are in preliminary stages as the clinical trials are still ongoing and there are no marketed products. Many of the patents are still pending.
Profiles of 162 companies involved in developing RNAi technologies are presented along with 235 collaborations. They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery. Out of these, 33 are developing RNAi-based therapeutics and 36 are involved in microRNAs. The bibliography contains selected 650 publications that are cited in the report. The text is supplemented with 38 tables and 14 figures.
Key Topics Covered:
Executive Summary
1. Technologies for suppressing gene function
2. RNAi Technologies
3. MicroRNA
4. Methods of delivery in RNAi
5. RNAi in Research
6. RNAi in drug discovery
7. Therapeutic applications of RNAi
8. Safety, regulatory and patent issues
9. Markets for RNAi Technologies
10. Companies involved in RNAi Technologies
11. References
For more information about this report visit http://www.researchandmarkets.com/research/g26s4b/rnai
Source: Jain PharmaBiotech
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article